Phase II Trial of Sorafenib in Metastatic Thyroid Cancer

PURPOSE: Based on the pivotal role of Ras-Raf-MAP-ERK signaling and vascular endothelial growth factor (VEGF) in papillary thyroid cancer (PTC), we conducted a phase II clinical trial of sorafenib targeting RAF and VEGF receptor kinases in PTC. PATIENTS AND METHODS: The primary end point was the obj...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Kloos, Richard T., Ringel, Matthew D., Knopp, Michael V., Hall, Nathan C., King, Mark, Stevens, Robert, Liang, Jiachao, Wakely, Paul E., Vasko, Vasyl V., Saji, Motoyasu, Rittenberry, Jennifer, Wei, Lai, Arbogast, Daria, Collamore, Minden, Wright, John J., Grever, Michael, Shah, Manisha H.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2009
Konular:
Original Reports
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2668972/
https://ncbi.nlm.nih.gov/pubmed/19255327
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.18.2717
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller